LAB 2 CHAPTER 2

On March 7, 2012, Celgene Corporation acquired Avila Therapeutics, Inc.

Access Celgenes 2012 annual report and answer the following regarding the acquisition:

A) Why did Celgene acquire Avila Therapeutics?

B) How did Celgene account for the in-process research and development product rights acquired in the combination?

C) How did Celgene determine the amount assigned to the contingent consideration portion of the purchase price?

D) What is the maximum potential contingent consideration payout to the former owners of Avila Therapeutics?

E) Prepare the entry Celgene would have made if Avila Therapeutics were dissolved after the combination.

F) Prepare the entry Celgene would have made if Avila Therapeutics continued as a separate wholly owned entity.

Please note - This was the only information given. There is no case or etc. supplements prior to this lab.